Mesalamine: Nursing Drug Guide, Renal Monitoring & NCLEX Review
5-ASA therapy for ulcerative colitis can quietly injure the kidneys—especially with NSAIDs, dehydration, or missed baseline BMP trends. Nurses must verify renal function before therapy, teach empty-stomach whole-tablet dosing, and distinguish mesalamine acute intolerance from a true colitis flare before escalating treatment.
Mesalamine is substantially excreted by the kidney. Labeling reports renal impairment including interstitial nephritis and, rarely, renal failure. Evaluate renal function before initiation and periodically during therapy. Concurrent nephrotoxic drugs, including NSAIDs, increase risk—monitor BMP trends and urine output. Discontinue mesalamine if renal function deteriorates. Mesalamine-induced acute intolerance syndrome (cramping, bloody diarrhea, fever, rash) can mimic ulcerative colitis flare—do not automatically increase dose when these symptoms appear after a new dose or formulation change.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every mesalamine dose, confirm baseline or trending creatinine is acceptable, NSAIDs are reconciled, and the patient can swallow tablets whole on an empty stomach with fluids. Rising creatinine, oliguria, or new cramping with bloody diarrhea after a dose change means hold, notify prescriber/pharmacist, and clarify flare versus acute intolerance before giving another dose.
Most common brand names
Mesalamine (5-aminosalicylic acid; 5-ASA) is available as multiple oral delayed-release and extended-release brands plus rectal formulations. The MAR product name, strength, and release type must match the prescriber order—formulations are not interchangeable.
Common oral brands include Delzicol, Asacol HD, Lialda, and Pentasa (dosing and release differ by product). Rectal mesalamine (enema/suppository) may appear on the plan for distal colitis. Do not substitute one 800 mg delayed-release tablet for two 400 mg products without prescriber and pharmacy verification per labeling.
Why we give it — Indications
Mesalamine is a topical anti-inflammatory aminosalicylate used primarily in inflammatory bowel disease. Nurses focus on correct oral administration timing, renal monitoring, interaction checks with NSAIDs and immunomodulators, and teaching patients to report worsening GI or renal symptoms early.
| Use | Detail |
|---|---|
| Ulcerative colitis (moderately active) | Mesalamine delayed-release 800 mg tablets are indicated for treatment of moderately active ulcerative colitis in adults at 1,600 mg (two tablets) three times daily for six weeks (total 4.8 g/day). Safety and effectiveness beyond six weeks have not been established for this product per labeling. |
| Other IBD presentations / formulations | Other mesalamine products (capsules, extended-release, rectal) carry indication-specific labeling for maintenance or distal disease—verify the exact product monograph. Pediatric safety for the 800 mg delayed-release tablet is not established; see other approved mesalamine products for pediatric use per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The mechanism is not fully understood; mesalamine appears to deliver topical anti-inflammatory action on colonic epithelium. It diminishes mucosal production of inflammatory mediators (prostaglandins and leukotrienes) in ulcerative colitis. Systemic absorption is limited (~20% from delayed-release tablets) but enough reaches circulation to cause renal, hepatic, and hypersensitivity reactions—nurses cannot treat oral mesalamine as “local only” for safety monitoring.
Dosing overview
Dosing varies by mesalamine product and indication. The values below reflect mesalamine delayed-release 800 mg tablets for moderately active ulcerative colitis per FDA labeling (May 2024). Always confirm the ordered brand, strength, and duration against the specific product monograph.
Missed dose: Not specified in the reviewed prescribing information for missed-dose instructions—contact prescriber/pharmacist per institutional protocol; do not double doses unless explicitly ordered.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (symptoms) | Not specified in the reviewed prescribing information for time to clinical improvement | GI improvement may take days to weeks; do not judge failure after a single dose |
| Peak (plasma) | Median Tmax ~24 hours (range 4–72 hours) after 800 mg delayed-release tablet under fasted conditions | Delayed-release design—systemic exposure still occurs (~20% absorbed) |
| Food effect | High-fat meal increased Cmax ~2.4-fold and AUC ~2.8-fold per labeling | Reinforce empty-stomach dosing to avoid excess absorption |
| Duration / course | Induction course 6 weeks for moderately active UC (this product) | Renal monitoring continues for entire course and maintenance therapies |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review baseline renal function (creatinine, BUN, eGFR) before starting therapy and ensure periodic BMP monitoring is ordered per labeling
- Reconcile NSAIDs and other nephrotoxic drugs; confirm allergy history to salicylates/aminosalicylates and prior reactions to related agents per chart and prior sulfasalazine reactions
- Verify correct product/strength on MAR; confirm patient can swallow tablets whole and understands empty-stomach timing (≥1 hour before and 2 hours after meals)
Contraindications
- Known or suspected hypersensitivity to salicylates, aminosalicylates, or any formulation ingredient
- Not specified in the reviewed prescribing information as additional absolute contraindications beyond hypersensitivity
- Clinical hold: deteriorating renal function, suspected acute intolerance syndrome, or serious hypersensitivity—discontinue and notify prescriber per warnings
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| NSAIDs and nephrotoxic agents | Increased risk of nephrotoxicity; monitor renal function and mesalamine-related adverse reactions per labeling | Hold or avoid concurrent NSAIDs when possible; trend creatinine; escalate if renal labs worsen |
| Azathioprine or 6-mercaptopurine | Increased risk of blood disorders and bone marrow suppression per labeling | Monitor CBC and platelets; report fever, bleeding, or severe fatigue; coordinate with pharmacy |
| Urinary normetanephrine testing (LC-ECD assay) | Spuriously elevated normetanephrine results due to metabolite similarity per labeling | Flag lab processing if hypertensive workup ordered; use alternative selective assay when applicable |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral delayed-release tablet swallowed whole with adequate fluids; take on an empty stomach at least 1 hour before and 2 hours after meals.
- Swallow tablets whole—do not cut, break, or chew (coating is essential for delayed release to the colon)
- Protect tablets from moisture; intact or partial tablet shells may appear in stool—report repeated occurrences to prescriber
- Do not substitute one 800 mg tablet for two 400 mg mesalamine products without pharmacy verification
High-fat meals increase mesalamine absorption and systemic exposure per labeling. Crushing or chewing destroys delayed release and can increase toxicity risk. If the patient cannot swallow whole tablets, contact prescriber/pharmacy for an appropriate formulation—do not crush standard delayed-release tablets.
Expected therapeutic response
- Decreased stool frequency, reduced bloody diarrhea, and improved abdominal comfort in ulcerative colitis over the treatment course
- Improving inflammatory markers when ordered (CRP/ESR) and prescriber assessment of remission and clinical remission assessments per gastroenterology plan
- Lack of improvement or worsening symptoms despite adherence may indicate flare, acute intolerance syndrome, or need for alternate therapy—requires prescriber review rather than silent dose changes
Red flags — Stop and act
Escalate promptly when renal, hypersensitivity, or intolerance cues appear—some mimic ulcerative colitis exacerbation.
- Rising creatinine/BUN, oliguria, edema, or flank pain suggesting renal injury
- New cramping, bloody diarrhea, fever, headache, malaise, pruritus, rash, or conjunctivitis after starting or increasing mesalamine (acute intolerance syndrome)
- Chest pain, dyspnea, or pericarditis symptoms; diffuse rash with mucosal involvement (SJS/TEN/DRESS concern)
- Jaundice, dark urine, or elevated liver enzymes in patients with liver disease
- Severe abdominal pain, hematemesis, or signs of GI bleeding/perforation—evaluate for complications beyond medication intolerance
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Headache, nausea, nasopharyngitis, abdominal pain | Most common (≥2% in trials) | Document; differentiate from intolerance syndrome if bloody diarrhea, fever, or rash appear |
| Worsening ulcerative colitis | Reported (≈2.3% in trials) | Notify prescriber; do not assume nonadherence alone—evaluate flare vs intolerance |
| Renal impairment (interstitial nephritis, renal failure) | Labeled warning; postmarketing reports | Trend BMP; hold and discontinue if renal function deteriorates per labeling |
| Mesalamine-induced acute intolerance syndrome | Labeled warning | Stop mesalamine; symptoms may mimic flare—prescriber determines next therapy |
| Hypersensitivity (myocarditis, pericarditis, hepatitis, pneumonitis, hematologic abnormalities) | Labeled warning; rare postmarketing | Stop drug; urgent evaluation when systemic hypersensitivity suspected |
| Severe cutaneous adverse reactions (SJS/TEN/DRESS/AGEP) | Postmarketing | Discontinue at first signs; emergency dermatology/allergy pathway |
| Blood dyscrasias (especially older adults; with azathioprine/6-MP) | Increased risk with concurrent myelotoxic drugs | Monitor CBC/platelets; report infection or bleeding symptoms |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Mesalamine is an aminosalicylate; salicylate-type toxicity may occur with overdose per labeling.
Signs of toxicity
- Nausea, vomiting, abdominal pain, tachypnea, hyperpnea, tinnitus
- Neurologic symptoms: headache, dizziness, confusion, seizures
- Severe intoxication: electrolyte and acid–base disturbances; renal and hepatic involvement possible
Overdose management
- No specific antidote is listed in the reviewed prescribing information
- Conventional therapy for salicylate toxicity may be beneficial, including GI decontamination when appropriate to limit further absorption
- Correct fluid and electrolyte imbalance with IV therapy and maintain adequate renal function
- Contact local poison control or medical toxicology services per facility protocol and local guidance
Mesalamine delayed-release is pH-dependent; consider formulation factors when treating suspected overdose per labeling.
Look-alike / sound-alike and error prevention
- Mesalamine vs sulfasalazine — different allergy cross-reactivity risk; verify salicylate/aminosalicylate allergies
- Brand/formulation mix-ups — Delzicol, Asacol HD, Lialda, Pentasa, and rectal products have different strengths and dosing; never interchange without pharmacy approval
- 800 mg tablet vs two 400 mg tablets — labeling states they are not substitutable
- Crushing delayed-release tablets — common administration error that increases systemic exposure and toxicity risk
- Duplicate 5-ASA therapy — oral plus rectal mesalamine without clear orders can increase toxicity; reconcile at admission and discharge
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Do not cut, break, or chew delayed-release tablets |
| Food timing | Empty stomach: ≥1 h before and 2 h after meals; high-fat meals increase absorption |
| Fluids | Adequate oral intake reduces nephrolithiasis risk per labeling |
| Storage | Protect from moisture; tablets may be dispensed without desiccant up to 6 weeks per labeling |
| Stool findings | Tablet shells in stool may occur—report if repeated; do not confuse with lack of effect alone |
| Iron content | 800 mg tablet contains iron in coating; consider total iron load with supplements per labeling |
| Ask pharmacy when | Product substitution, inability to swallow whole tablets, NSAID alternatives, or renal dose/hold questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment, dehydration, or nephrotoxic co-therapy | Greater risk of toxic reactions when renal function is impaired; evaluate renal function prior to initiation and periodically; discontinue if function deteriorates |
| Older adults (≥65) | Postmarketing reports suggest higher incidence of blood dyscrasias with mesalamine-containing products—monitor CBC and platelets during therapy |
| Concurrent azathioprine/6-mercaptopurine or pre-existing liver disease | Increased myelotoxicity risk and reports of hepatic failure in liver disease—coordinate labs and prescriber review |
| Pregnancy | Limited published human data are insufficient to inform a drug-associated risk; animal studies showed no fetal harm at exposures up to ~0.97–1.95 times the recommended human dose. Use during pregnancy only if potential benefit justifies potential risk after discussion with prescriber per labeling. |
| Lactation | Mesalamine and its N-acetyl metabolite are present in human milk in small amounts; limited reports of diarrhea in breastfed infants. Monitor breastfed infants for diarrhea; consider developmental benefits of breastfeeding alongside maternal clinical need per labeling. See LactMed for additional context. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function at baseline and periodically (creatinine, BUN, eGFR); consider urinalysis when clinically indicated; track urine output and hydration
- CBC and platelets when elderly or when combined with azathioprine/6-mercaptopurine; liver enzymes in patients with liver disease
- GI symptoms (stool frequency, blood, nausea/vomiting, pain), hydration status, rash/photosensitivity, and adherence to empty-stomach whole-tablet dosing
Document
- Product name/strength, dose, time relative to meals, and whether tablets taken whole
- Baseline and trending renal labs, NSAID reconciliation, hold actions, and prescriber/pharmacy notifications
- Patient teaching on fluid intake, symptom diary (flare vs intolerance), and repeated tablet shells in stool
Patient teaching
- Take mesalamine on an empty stomach (≥1 hour before and 2 hours after meals) with adequate fluids—do not crush or chew tablets
- Avoid NSAIDs unless prescriber approves; report decreased urination, swelling, flank pain, or blood tests showing rising creatinine
- Report cramping, bloody diarrhea, fever, rash, or breathing difficulty—these may be acute intolerance or hypersensitivity, not just a flare
- Maintain hydration to reduce kidney stone risk; report severe side/back pain or blood in urine (hematuria) per labeling; report severe side/back pain or blood in urine
- Urine may look reddish-brown after contact with bleach-containing toilet water—notify your clinician only if urine is discolored before it hits the bowl
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Rising creatinine or oliguria suggesting renal injury—hold and notify prescriber/pharmacist; labeling directs discontinuation if renal function deteriorates
- Suspected mesalamine-induced acute intolerance syndrome or serious hypersensitivity (widespread rash, dyspnea, pericarditis symptoms)
- Patient cannot swallow whole tablets or repeatedly vomits doses—clarify formulation with prescriber/pharmacy
- New significant NSAID or nephrotoxic drug started without renal monitoring plan
- Particulate/discolored tablets, wrong product/strength on MAR, or moisture-damaged supply
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Outpatient GI clinics and medical-surgical units use mesalamine for colitis maintenance and induction—use medication reconciliation at every transition. The highest-impact nursing steps are renal surveillance, NSAID reconciliation, and distinguishing intolerance from flare before dose escalation.
1. Check-before-you-give protocol
- Right patient, drug product, strength, and dose—confirm 800 mg delayed-release tablet matches order (not 400 mg substitution)
- Review latest creatinine/eGFR and active NSAID orders; assess hydration and urine output trends
- Confirm empty-stomach window and ability to swallow whole; inspect tablet integrity and storage/moisture exposure
- Screen for new GI toxicity symptoms (bloody diarrhea, cramping, fever) or rash since last dose
2. High-alert and safety badge
Not a standard high-alert medication, but requires renal vigilance comparable to nephrotoxic oral therapiesTreat mesalamine with structured renal monitoring and interaction checks—especially when patients self-administer at home and use OTC ibuprofen for joint pain or headache.
3. Clinical workflow: hold and question rules
- If creatinine increases from personal baseline or eGFR falls, hold mesalamine and notify prescriber same day with BMP trend
- If acute intolerance symptoms appear after dose increase, hold and clarify flare versus intolerance before escalating therapy
- Serious cutaneous reaction or anaphylaxis symptoms: stop mesalamine permanently per labeling and activate emergency pathway
4. Critical teach-back questions
- “How should you take mesalamine tablets in relation to meals?” (Patient should state empty stomach—at least 1 hour before and 2 hours after eating—and swallow tablets whole with fluids without crushing.)
- “Which symptoms should you report right away while on mesalamine?” (Patient should name decreased urination, swelling, flank pain, bloody diarrhea with fever, severe rash, or breathing difficulty—and avoid starting ibuprofen without asking the team.)
5. Care coordination
Gastroenterology / prescriber:: Define induction versus maintenance plan, duration of therapy, and when to switch formulation or escalate to immunomodulator/biologic therapy
Pharmacist:: Verify correct mesalamine product interchange, NSAID alternatives, renal lab scheduling, and azathioprine/6-MP monitoring when combined
🧠 Quick mental checklist
- Renal labs current and trending acceptable before this dose?
- Any NSAID, dehydration, or nephrotoxic drug on the profile?
- Can the patient swallow whole tablets on an empty stomach with fluids?
- Is worsening GI symptoms a flare, acute intolerance, or infection?
- Correct product/strength—not substituting 800 mg for two 400 mg tablets without approval?
Mesalamine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for mesalamine renal and intolerance safety using a tabbed outpatient case (MAR, labs, I&O, nursing notes), then priority action, cue recognition (SATA), creatinine trend interpretation, matrix urgency sorting, clinical judgment, and administration cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Mesalamine DR 800 mg — two tablets PO TID (4.8 g/day) — 0800, 1400, 2000
- Ibuprofen 400 mg PO TID PRN joint pain — patient self-administered ×3 yesterday
- Ferrous sulfate 325 mg PO daily — 0900
- No mesalamine dose held on MAR
- Baseline (pre-therapy): creatinine 1.0 mg/dL; BUN 16 mg/dL; eGFR 82 mL/min/1.73 m²
- Week 1: creatinine 1.2 mg/dL; BUN 20 mg/dL; eGFR 68 mL/min/1.73 m²
- Today (week 2): creatinine 1.6 mg/dL; BUN 26 mg/dL; eGFR 48 mL/min/1.73 m²
- Repeat BMP and urine studies ordered
- 24 h intake: 1,450 mL oral + IV fluids 0 mL
- 24 h urine output: 820 mL (≈34 mL/h) — down from 1,300 mL prior day
- Patient reports dark, concentrated urine since yesterday
- Weight +1.2 kg in 48 h; mild ankle edema noted
- 28-year-old with moderately active ulcerative colitis; week 2 of mesalamine induction
- Reports improved stool frequency but new mild flank discomfort and fatigue
- Uses OTC ibuprofen for knee pain without telling clinic until today
- 1800: denies shortness of breath; abdomen soft with mild diffuse tenderness; no gross blood on last stool
Answer key & rationale
Frequently asked questions
When should a nurse hold mesalamine and contact the prescriber or pharmacist?
Hold when renal function deteriorates (rising creatinine, oliguria), when acute intolerance syndrome is suspected (cramping, bloody diarrhea, fever, rash), for serious hypersensitivity or severe cutaneous reactions, if tablets cannot be swallowed whole, or when nephrotoxic drugs such as NSAIDs are used without a monitoring plan. Labeling directs discontinuation if renal function worsens during therapy.
Why must patients avoid NSAIDs while taking mesalamine?
FDA labeling states concurrent nephrotoxic agents including NSAIDs may increase nephrotoxicity with mesalamine. Mesalamine is substantially excreted by the kidney; monitor renal function and mesalamine-related adverse reactions when NSAIDs cannot be avoided.
How is mesalamine-induced acute intolerance syndrome different from a colitis flare?
Acute intolerance can mimic flare with cramping, abdominal pain, bloody diarrhea, fever, headache, malaise, pruritus, rash, and conjunctivitis—reported after starting or increasing mesalamine. Symptoms usually improve when mesalamine is stopped. Do not assume flare and escalate dose without prescriber evaluation.
What labs should nurses monitor on mesalamine?
Evaluate renal function before initiation and periodically (creatinine, BUN, eGFR). Monitor CBC and platelets in older adults or with azathioprine/6-mercaptopurine. Monitor liver enzymes in patients with liver disease. Trend results against baseline and hold or discontinue per labeling when function deteriorates.
Is there an antidote for mesalamine overdose?
No specific antidote is listed. Overdose may cause salicylate-type toxicity (nausea, vomiting, abdominal pain, tinnitus, confusion, seizures). Management includes supportive care and conventional salicylate toxicity measures such as GI decontamination when appropriate, fluid/electrolyte correction, and maintaining renal function. Contact local poison control or toxicology services per facility protocol.
Can mesalamine tablets be crushed or split?
No. Delayed-release mesalamine tablets must be swallowed whole. Cutting, breaking, or chewing destroys the coating and alters release and absorption. If the patient cannot swallow whole tablets, contact the prescriber or pharmacist for an appropriate formulation.
References
-
U.S. National Library of Medicine. Mesalamine delayed-release tablets, 800 mg — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00f77203-3615-47e8-ae25-6e1cf8a2a00a
-
U.S. National Library of Medicine. DELZICOL (mesalamine) delayed-release capsules — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b02324-9430-4269-825f-8fcac5eeaefb
-
Drugs and Lactation Database (LactMed). Mesalamine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK44358/
-
U.S. National Library of Medicine. Mesalamine — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a688084.html
-
U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.